K
Kenneth M. Bodner
Researcher at Dow Chemical Company
Publications - 51
Citations - 1624
Kenneth M. Bodner is an academic researcher from Dow Chemical Company. The author has contributed to research in topics: Standardized mortality ratio & Cancer. The author has an hindex of 20, co-authored 51 publications receiving 1553 citations.
Papers
More filters
Journal ArticleDOI
Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats
Keith A. Johnson,S. J. Gorzinski,Kenneth M. Bodner,Roy A. Campbell,Claude H. Wolf,Marvin A. Friedman,Richard W. Mast +6 more
TL;DR: A target organ effect, characterized by degeneration of peripheral nerves, was observed in rats receiving 2.0 mg/kg/day and increased incidence of central nervous system tumors when compared to historical controls but not whenCompared to concurrent controls.
Journal ArticleDOI
Have sperm counts been reduced 50 percent in 50 years? A statistical model revisited
TL;DR: To reanalyze data that were used in a linear model to predict that mean sperm counts have been reduced globally by approximately 50% in the last 50 years, several different statistical models were reanalyzed.
Journal ArticleDOI
Validation of work histories obtained from interviews
TL;DR: A nested case-control study of lung cancer conducted in 1985 among a cohort of 19,608 male workers at a Texas chemical production facility provided an opportunity to assess the validity of occupational histories obtained from interviews.
Journal ArticleDOI
Survey of reproductive events of wives of employees exposed to chlorinated dioxins
TL;DR: Overall, no statistically significant associations were found between any exposure and pregnancy outcome, either before or after stratification by pertinent sets of up to nine covariables.
Journal ArticleDOI
Mortality among workers engaged in the development or manufacture of styrene-based products--an update
TL;DR: Mortality from leukemia was slightly less than expected during the updated period, in contrast to an excess of lymphatic leukemia observed in the original period, and small elevations in risk of other types of lymphatics cancer, particularly multiple myeloma, persisted.